Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its fourth quarter and full year 2012 financial results on Wednesday, March 6, 2013, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.
On Thursday, March 7, 2013, at 9 a.m. ET, Furiex will conduct a live conference call and audio webcast to discuss financial results and product portfolio. A Q&A session will follow. The conference call will be broadcast live over the Internet and will also be available using the following direct dial numbers:
Participant dial-in: | +1 877 677 9122 (U.S./Canada) | |
| +1 708 290 1401 (International) | |
Conference ID: | 94872897 |
All interested parties can access the webcast through the Presentations
& Events link in the Investors section of the Furiex website at www.furiex.com.
The webcast will be archived shortly after the call for on-demand replay.
About Furiex
Furiex Pharmaceuticals is a drug development
collaboration company that uses innovative clinical development design
to accelerate and increase value of drug development programs by
advancing them through the drug discovery and development process in a
cost-efficient manner. Our drug development programs are designed and
driven by a core team with extensive drug development experience. The
company collaborates with pharmaceutical and biotechnology companies and
has a diversified product portfolio and pipeline with multiple
therapeutic candidates, including one Phase III-ready asset, two
compounds in Phase III development, one of which is with a partner,
three products on the market and a fourth approved in the United States
but not yet launched. The company's mission is to develop innovative
medicines faster and at a lower cost, thereby improving profitability
and accelerating time to market while providing life-improving therapies
for patients. For more information, visit www.furiex.com.
Furiex Pharmaceuticals
Media/Analysts/Investors:
Sailash
Patel, 919.456.7814
sailash.patel@furiex.com